ReviewAllergy2020
A compendium answering 150 questions on COVID-19 and SARS-CoV-2.
Review in Allergy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 1 synthesis or guideline pooled it, 149 citations in OpenAlex.
- Communication to promote and support physical distancing for COVID-19 prevention and control: a rapid reviewThe Cochrane database of systematic reviews · 2023Pooled it
- Homeopathy for COVID-19 in primary care: A randomized, double-blind, placebo-controlled trial (COVID-Simile study).Journal of integrative medicine · 2022Trial
- Asthma exacerbation prevalence during the COVID-19 lockdown in a moderate-severe asthma cohort.BMJ open respiratory research · 2021Trial
- Assessing the Burden of Thromboembolic Complications in Outpatient COVID-19 Cases: A Focused Study on Patients Followed in Primary Care.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025Article
- Immunobiology of COVID-19: Mechanistic and therapeutic insights from animal models.Zoological research · 2024Review
- Article
- Impulse oscillometry and its independent role in the diagnosis of chronic obstructive pulmonary disease.Heliyon · 2024Article
- Clinical and immunologic features of co-infection in COVID-19 patients, along with potential traditional Chinese medicine treatments.Frontiers in immunology · 2024Article
- Evaluating the Use of a Robot in a Hematological Intensive Care Unit: A Pilot Study.Sensors (Basel, Switzerland) · 2023Article
- Genetic variants associated with SARS-CoV-2 infection also affect lung function and asthma severity.Heliyon · 2023Article
- Value of the Lymphocyte Transformation Test for the Diagnosis of Drug-Induced Hypersensitivity Reactions in Hospitalized Patients with Severe COVID-19.International journal of molecular sciences · 2023Article
- Article
- COVID-19 Biogenesis and Intracellular Transport.International journal of molecular sciences · 2023Review
- Recent developments in the immunopathology of COVID-19.Allergy · 2023Review
- Long-term effects of homologous and heterologous SARS-CoV-2 vaccination on humoral and cellular immune responses.Allergy · 2022Article
- Article
- Serological testing for SARS-CoV-2 antibodies in clinical practice: A comparative diagnostic accuracy study.Allergy · 2022Article
- Chronic Rhinosinusitis and COVID-19.The journal of allergy and clinical immunology. In practice · 2022Review
- COVID-19 symptomatology and compliance with community mitigation strategies in Latin America early during the COVID-19 pandemic.Preventive medicine reports · 2022Article
- Cutaneous and systemic hyperinflammation drives maculopapular drug exanthema in severely ill COVID-19 patients.Allergy · 2022Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
42 authors at 20 institutions in 23 countries.
Funding
Abstract
In December 2019, China reported the first cases of the coronavirus disease 2019 (COVID-19). This disease, caused by the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), has developed into a pandemic. To date, it has resulted in ~9 million confirmed cases and caused almost 500 000 related deaths worldwide. Unequivocally, the COVID-19 pandemic is the gravest health and socioeconomic crisis of our time. In this context, numerous questions have emerged in demand of basic scientific information and evidence-based medical advice on SARS-CoV-2 and COVID-19. Although the majority of the patients show a very mild, self-limiting viral respiratory disease, many clinical manifestations in severe patients are unique to COVID-19, such as severe lymphopenia and eosinopenia, extensive pneumonia, a "cytokine storm" leading to acute respiratory distress syndrome, endothelitis, thromboembolic complications, and multiorgan failure. The epidemiologic features of COVID-19 are distinctive and have changed throughout the pandemic. Vaccine and drug development studies and clinical trials are rapidly growing at an unprecedented speed. However, basic and clinical research on COVID-19-related topics should be based on more coordinated high-quality studies. This paper answers pressing questions, formulated by young clinicians and scientists, on SARS-CoV-2, COVID-19, and allergy, focusing on the following topics: virology, immunology, diagnosis, management of patients with allergic disease and asthma, treatment, clinical trials, drug discovery, vaccine development, and epidemiology. A total of 150 questions were answered by experts in the field providing a comprehensive and practical overview of COVID-19 and allergic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.